Kronos Bio, Inc.
Kronos Bio, Inc. (KRON): 3 pipeline candidates · ~24 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
23.7 months
D/E 0.35 · 0% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for Kronos Bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$93.6M
Quarterly Burn
$12.8M
Runway
23.7 mo
Revenue
$1.9M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in Kronos Bio, Inc.'s pipeline?
Kronos Bio, Inc. (KRON) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Kronos Bio, Inc.'s lead drug candidate?
Kronos Bio, Inc.'s most advanced tracked candidate is kb-0742 (Phase 2) for MYC-amplified and other transcriptionally addicted solid tumors.
What is Kronos Bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Kronos Bio, Inc. has approximately 23.7 months of cash runway.
Who is the CEO of Kronos Bio, Inc.?
Norbert Bischofberger, Ph.D. is the chief executive officer of Kronos Bio, Inc. (KRON).
Get the full picture on Kronos Bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.